Wednesday, July 16, 2008

Spotlight on emerging Columbus Tech Companies


Developers of a painless, non-invasive glucose monitor using proprietary analysis techniques to overcome obstacles of spectroscopic based non-invasive instruments. A recipient of $125,000 in First Fifty funds with additional funding from individual angel investors. The company is eligible for Ohio’s Technology Investment Tax Credit (TITC) program.

InVasc Therapeutics

Specializes in target-specific drug discovery with several potential drug therapies at the pre-clinical stage. The company has developed a proprietary approach to drug discovery that uses molecular structures and an application-based platform that dramatically decreases the time and expense of current large-scale “mining” discovery techniques. The InVasc process is the result of university-based research at Emory University and The Ohio State University.

Labels: , , ,


Post a Comment

Subscribe to Post Comments [Atom]

<< Home